Pharma AI Tracker

At the 2024 J.P. Morgan Healthcare Conference, Celltrion said its CEO shared plans to expand into digital healthcare with a company-owned data bank. That bank would use artificial intelligence to synthesize Celltrion's clinical and genomic data.

AstraZeneca built a knowledge graph combining public adverse-event and exposure data to speed COVID-19 vaccine safety analyses and periodic reporting.

Maestro gives a cross-functional view of manufacturing work for each patient in the INT program. An AI scheduling algorithm fits each patient's batch into a timeline based on real-time capacity.

Integrated AI algorithms read tumor and blood sequencing data to predict up to 34 neoantigens for each patient's individualized cancer therapy.

Merck KGaA launched AIDDISON, drug discovery software that it says combines generative AI, machine learning and computer-aided drug design to speed up drug development.

With AWS and Accenture, Merck built a cloud inference pipeline (HawkAVI) that analyses large volumes of inspection-machine data from its manufacturing sites.

Partners: AWS, Accenture

Moderna's in-house generative AI chat tool, launched in May 2023 after two weeks of development. Nearly 65% of employees were active users by October 2023.

Pfizer stood up Vox, its own internally approved generative AI platform on AWS, and described it in a re:Invent keynote as the base for many use cases.

Partners: AWS

AbbVie's ARCH platform centralizes R&D data and hosts chemists' predictive models, which AbbVie says are rerun on 30-day cycles; AbbVie also says its generative AI platform is being embedded into ARCH.

PharmaEssentia USA, announcing abstracts for the MPN Congress and ASH, said the program included an AI-based discovery analysis and listed a presentation described as a causal-AI dissection of RNA-seq data sets that pinpoints connections between myeloproliferative neoplasms and neurodegenerative diseases.

Insmed announced a collaboration with Google Cloud to use generative AI across drug discovery, drug development, drug commercialization and enabling functions. The release says the work runs on Google Cloud infrastructure and uses Google Cloud's AI technology, and that Insmed has built a generative AI search capability using Vertex AI Search trained on its internal documentation, plus separate indexed access to external medical publications.

Partners: Google Cloud

In the same release, Insmed says it is advancing an early-stage research engine that includes artificial intelligence-driven protein engineering, alongside gene therapy and protein manufacturing.

Incyte's 2022 global responsibility report says patients in its vitiligo clinical trials have an AI-driven tool for tracking progress. It says a smartphone app launched in 2022 lets patients and healthcare providers capture, share, compare and review results, and that the Vitiligo Assessment Tool uses machine learning to analyze skin images for changes in skin characteristics.

Manufacturing staff use AI/ML to find similar past deviations across sites and to automate review and trending of minor deviations. Sanofi reported a 60% cut in closure time.

An AI app built with Aily Labs that pulls together internal data across functions to give staff real-time views and predictions. Sanofi announced its company-wide scale-up in June 2023.

Partners: Aily Labs

Use of plai in biopharma supply chain to flag likely low-inventory positions ahead of time so planners can act earlier.

Partners: Aily Labs

Galderma's Cetaphil brand unveiled the Cetaphil AI Skin Analysis tool on the Cetaphil U.S. website. The release says the tool is powered by Perfect Corp's AI Skin Analysis technology and that the scanning technology uses AI deep learning to deliver personalized skin assessments in seconds.

Partners: Perfect Corp

Bayer completed the acquisition of Blackford Analysis, which it calls a global imaging AI platform and solutions provider. The release says Blackford is now a wholly owned subsidiary and continues to operate.

Partners: Blackford Analysis

Bayer and Google Cloud announced a collaboration that applies Google Cloud TPUs, described as accelerators designed to run machine-learning models and computationally intensive workloads, to accelerate and scale Bayer's quantum chemistry calculations.

Partners: Google Cloud

PharmaEssentia announced the PharmaEssentia Innovation Research Center in the Boston area and said data scientists at the center will use artificial intelligence and machine learning to inform new target and indication selections.

GSK says it will work with Tempus, using Tempus's AI/ML capability and de-identified patient data, to improve clinical trial design, speed up enrolment and identify drug targets. GSK made a $70 million initial payment.

Partners: Tempus

Roivant's prospectus says the in silico small-molecule discovery engine at Roivant Discovery is powered by QUAISAR, which it names as QUantum, AI and Structure-Activity Relationships. The same section says those capabilities predict how molecules interact and power in silico assays, and that the engine includes a suite of degrader-specific machine-learning tools the company has developed.

The same prospectus says Roivant aggregated clinical-trial technologies at its subsidiary Lokavant. It says algorithms trained on operational metadata from over 2,000 trials are designed to identify the most important risks in time for researchers to intervene, and that Lokavant's software is in use in Roivant's late-stage trials and in trials run by other sponsors and contract research organizations.

UCB says its Statistical Science and Innovation group filed a patent application centred on an improved machine learning method that allows AI to predict an outcome or provide decision guidance, and that this innovation has already been used to inform patient stratification, clinical trial design and precision-medicine approaches in Parkinson's disease and epilepsy.